https://www.fiercepharma.com/pharma/mid-decade-crisis-looms-car-t-cell-therapy
Worth listening to Elliot around the 16 min mark.
https://us02web.zoom.us/webinar/register/WN_1pHYeOH2QQSAwpw_KsOdYg
They're leveraging the CAR from CLTX and the cell from CORE NK program.
- Accelerate the time to treatment to patients
-Broaden the number of patients that could potentially receive the therapy as it could be manufactured at a greater scale with many many patients worth of material from one manufacturing run.
What's our IP going to be worth if we can make the treatment cheaper, accessible to more patients and the ease the burden on the hospital system?
Ann: Positive in vitro data for CHM 1301 CAR NK cells-supplement, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |